Achieve Life Sciences (ACHV) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T12:45:14.142Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:45:14.142Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -58,051,000
Quote market capitalization: 719,639,590
Total debt · period ending 2026-06-30: 14,948,000
Cash · period ending 2026-06-30: 47,958,000

FMP input reference: c295c1623f78bdf77a886cf07ea1e6d336f06da24b8c95eb76ef4971c7c9c79e

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

ACHV EBITDA Yield Metrics

EBITDA YIELD

N/A

ACHV Competitors' EBITDA Yield

ACHV

Achieve Life Sciences, Inc.

Current

Market Cap

$719.64M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COLL

Collegium Pharmaceutical, Inc.

vs ACHV

Market Cap

$709.33M

EBITDA Yield

35.16%

TTM Avg

23.06%

3Y Avg

19.27%

5Y Avg

16.31%

HELP

Helus Pharma Inc.

vs ACHV

Market Cap

$707.86M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVR

Anteris Technologies Global Corp.

vs ACHV

Market Cap

$734.10M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FTH

Faeth Therapeutics, Inc.

vs ACHV

Market Cap

$698.60M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CADL

Candel Therapeutics, Inc.

vs ACHV

Market Cap

$749.55M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANNX

Annexon, Inc.

vs ACHV

Market Cap

$688.14M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs ACHV

Market Cap

$675.41M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVTX

Avalo Therapeutics, Inc.

vs ACHV

Market Cap

$767.46M

EBITDA Yield

N/A

TTM Avg

4.15%

3Y Avg

4.09%

5Y Avg

4.09%

ATTO

Attovia Therapeutics, Inc.

vs ACHV

Market Cap

$774.32M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Achieve Life Sciences, Inc. (ACHV)	$719.64M	N/A	N/A	N/A	N/A
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.33M	35.16%	23.06%	19.27%	16.31%
Helus Pharma Inc. (HELP)vs ›	$707.86M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$734.10M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$698.60M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$749.55M	N/A	N/A	N/A	N/A
Annexon, Inc. (ANNX)vs ›	$688.14M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$675.41M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$767.46M	N/A	4.15%	4.09%	4.09%
Attovia Therapeutics, Inc. (ATTO)vs ›	$774.32M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ACHV EBITDA Yield Metrics

ACHV Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics